Quantcast
Last updated on April 19, 2014 at 1:20 EDT

BD Announces Results for 2011 Fourth Fiscal Quarter and Full Year

November 2, 2011

FRANKLIN LAKES, N.J., Nov. 2, 2011 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the fourth fiscal quarter ended September 30, 2011, representing an increase of 9.5 percent from the prior-year period, or 4.0 percent on a foreign currency-neutral basis.

For the full fiscal year ended September 30, 2011, BD reported revenues of $7.829 billion, representing an increase of 6.2 percent over the prior year. On a foreign currency-neutral basis, revenues increased 2.9 percent, despite an unfavorable comparison to the prior year of about 2.0 percentage points due to strong sales related to the H1N1 flu pandemic, supplemental spending in Japan and stimulus spending in the U.S. in fiscal year 2010.

“We are pleased with our solid finish to fiscal year 2011. Despite a challenging business environment, all segments contributed to our success and growth,” said Vincent A. Forlenza, Chief Executive Officer and President. “We will continue to drive operational efficiencies and make capital and R&D investments to support our innovation strategy as we look to fiscal year 2012 and beyond.”

Update on the Acquisition of Carmel Pharma, AB

As announced in August 2011, the Company completed the acquisition of Carmel Pharma, AB, a Swedish company that manufactures the BD PhaSeal(TM) System. This is the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials. The financial impact of the acquisition on our fourth quarter results was in line with our guidance.

Fourth Quarter Earnings and Analysis of the Full Fiscal Year 2011 and 2010 Earnings

Reported diluted earnings per share from continuing operations for the fourth quarter were $1.36, compared with $1.24 in the prior-year period, representing a 9.7 percent increase. Current quarter results included a non-cash charge of $9 million, or $0.03 per share from continuing operations, resulting from the discontinuance of a research program within the Diagnostic Systems unit. Excluding this item, adjusted diluted earnings per share from continuing operations increased by 12.1 percent to $1.39, compared with $1.24 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fourth quarter increased by 8.1 percent.

For the full fiscal year ended September 30, 2011, reported diluted earnings per share from continuing operations were $5.59, compared with $4.90 in the prior fiscal year, representing an increase of 14.1 percent. Excluding the aforementioned charge of $9 million, or $0.03 per share from continuing operations, and the 2010 fiscal year charge of $0.04 per share from continuing operations related to healthcare reform impacting Medicare Part D reimbursements, adjusted diluted earnings per share from continuing operations increased by 13.8 percent to $5.62, compared with $4.94 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fiscal year increased 8.1 percent.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.055 billion, representing an increase of 10.0 percent compared with the prior-year period. Revenues increased 3.8 percent on a foreign currency-neutral basis. Segment revenue growth reflected strong Diabetes Care and international safety sales, along with solid sales of Pharmaceutical Systems products. For the twelve-month period ended September 30, 2011, BD Medical revenues increased 5.6 percent, or 2.3 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $642 million, representing an increase of 8.6 percent compared with the prior-year period, or 3.8 percent on a foreign currency-neutral basis. Revenues reflected solid growth in both the Women’s Health and Cancer and the Infectious Disease product offerings within the Diagnostic Systems unit. For the twelve-month period ended September 30, 2011, BD Diagnostics revenues increased 7.0 percent, or 3.9 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $354 million, representing an increase of 9.6 percent compared with the prior-year period. Revenues increased 4.7 percent on a foreign currency-neutral basis, primarily driven by instrument and reagent sales in the Cell Analysis unit. For the twelve-month period ended September 30, 2011, BD Biosciences revenues increased 6.7 percent, or 3.2 percent on a foreign currency-neutral basis.

Geographic Results

Fourth quarter revenues in the U.S. were $843 million, representing an increase of 1.3 percent compared with the prior-year period. Revenues outside of the U.S. were $1.208 billion, representing an increase of 16.0 percent compared with the prior-year period, or 6.1 percent on a foreign currency-neutral basis. International revenue growth was driven by continued strength in safety sales and strong growth in emerging markets. For the twelve-month period ended September 30, 2011, revenues in the U.S. were $3.356 billion, representing an increase of 2.1 percent compared with the prior-year period. Revenues outside of the U.S. were $4.473 billion, representing an increase of 9.5 percent compared with the prior-year period, or 3.6 percent on a foreign currency-neutral basis.

Fiscal 2012 Outlook for Full Year

The Company estimates that reported revenues for the full fiscal year 2012 will increase about 1 to 3 percent, or 2 to 4 percent on a foreign currency-neutral basis. Our guidance reflects the anticipated effects of lower healthcare utilization, reduced research funding and global macroeconomic conditions. The Company expects reported diluted earnings per share from continuing operations for fiscal year 2012 to be between $5.75 and $5.85. The Company also plans to repurchase, subject to market conditions, $1.5 billion of its common stock in fiscal year 2012, and fund the repurchases through ongoing cash flow and the issuance of debt.

Conference Call Information

A conference call regarding BD’s fourth quarter results and its expectations for the full fiscal year 2012 will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Wednesday, November 2, 2011. The slides will be available concurrent with the issuance of this press release at www.bd.com/investors. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 855-859-2056 (domestic) and 404-537-3406 (international) through the close of business on Wednesday, November 9, 2011, access code 16826583.

Non-GAAP Financial Measures

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled “Fiscal 2012 Outlook”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369


    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per share data)

                                                                Three Months Ended September 30,
                                                                2011             2010       % Change
                                                                ----             ----       --------

    REVENUES                                              $2,050,795       $1,873,195             9.5

    Cost of products
     sold                                                    999,352          900,933            10.9
    Selling and
     administrative                                          487,232          438,139            11.2
    Research and
     development                                             126,054          123,606             2.0
    ------------                                             -------          -------             ---
    TOTAL OPERATING
     COSTS
         AND EXPENSES                                      1,612,638        1,462,678            10.3
         ------------                                      ---------        ---------            ----

    OPERATING INCOME                                         438,157          410,517             6.7

    Interest income                                            1,915           14,594           (86.9)
    Interest expense                                         (22,334)         (12,278)           81.9
    Other income, net                                          1,272            1,285            (1.0)
    -----------------                                          -----            -----            ----

    INCOME FROM
     CONTINUING
     OPERATIONS BEFORE
         INCOME TAXES                                        419,010          414,118             1.2

    Income tax
     provision                                               117,606          121,065            (2.9)
    ----------                                               -------          -------            ----

    INCOME FROM
     CONTINUING
     OPERATIONS                                              301,404          293,053             2.8

    (LOSS) INCOME FROM
     DISCONTINUED
     OPERATIONS
       NET OF INCOME TAX
        PROVISION OF
                       $81 AND $27,645, RESPECTIVELY          (1,424)         103,642              NM
                       -----------------------------          ------          -------              --

    NET INCOME                                              $299,980         $396,695           (24.4)
    ----------                                              --------         --------           -----

    EARNINGS PER SHARE

    Basic:
    Income from
     continuing
     operations                                                $1.39            $1.27             9.4
    (Loss) Income from
     discontinued
     operations                                               $(0.01)           $0.45              NM
    Net income (1)                                             $1.38            $1.71           (19.3)

    Diluted:
    Income from
     continuing
     operations                                                $1.36            $1.24             9.7
    (Loss) Income from
     discontinued
     operations                                               $(0.01)           $0.44              NM
    Net income (1)                                             $1.36            $1.68           (19.0)

    AVERAGE SHARES
     OUTSTANDING

         Basic                                               216,726          231,396
         Diluted                                             220,859          236,316
         -------                                             -------          -------

    NM - Not Meaningful
    (1) Total per share
     amounts may not
     add due to
     rounding.

                                                                                               Page 1


    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per share data)

                                                               Twelve Months Ended September 30,
                                                                2011             2010        % Change
                                                                ----             ----        --------

    REVENUES                                              $7,828,904       $7,372,333              6.2

    Cost of products
     sold                                                  3,737,352        3,543,183              5.5
    Selling and
     administrative                                        1,851,774        1,721,356              7.6
    Research and
     development                                             476,496          430,997             10.6
    ------------                                             -------          -------             ----
    TOTAL OPERATING
     COSTS
         AND EXPENSES                                      6,065,622        5,695,536              6.5
         ------------                                      ---------        ---------              ---

    OPERATING INCOME                                       1,763,282        1,676,797              5.2

    Interest income                                           43,209           35,129             23.0
    Interest expense                                         (84,019)         (51,263)            63.9
    Other (expense)
     income, net                                              (6,209)             497               NM
    ---------------                                           ------              ---              ---

    INCOME FROM
     CONTINUING
     OPERATIONS BEFORE
         INCOME TAXES                                      1,716,263        1,661,160              3.3

    Income tax
     provision                                               451,411          484,820             (6.9)
    ----------                                               -------          -------             ----

    INCOME FROM
     CONTINUING
     OPERATIONS                                            1,264,852        1,176,340              7.5

    INCOME FROM
     DISCONTINUED
     OPERATIONS
       NET OF INCOME TAX
        PROVISION OF
                      $792 AND $40,703, RESPECTIVELY           6,142          141,270               NM
                      ------------------------------           -----          -------               --

    NET INCOME                                            $1,270,994       $1,317,610             (3.5)
    ----------                                            ----------       ----------             ----

    EARNINGS PER SHARE

    Basic:
    Income from
     continuing
     operations                                                $5.72            $5.02             13.9
    Income from
     discontinued
     operations                                                $0.03            $0.60            (95.0)
    Net income                                                 $5.75            $5.62              2.3

    Diluted:
    Income from
     continuing
     operations                                                $5.59            $4.90             14.1
    Income from
     discontinued
     operations                                                $0.03            $0.59            (94.9)
    Net income                                                 $5.62            $5.49              2.4

    AVERAGE SHARES
     OUTSTANDING

         Basic                                               221,175          234,328
         Diluted                                             226,280          240,136
         -------                                             -------          -------

    NM - Not Meaningful

                                                                                                Page 2


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)

                                                  Three Months Ended September 30,
                                                    2011             2010      % Change
                                                    ----             ----      --------

    BD MEDICAL
    ----------
       United States                          $404,301         $400,231           1.0
       International                           650,290          558,374          16.5
    -------------                              -------          -------
    TOTAL                                   $1,054,591         $958,605          10.0
    -----                                   ----------         --------          ----

    BD DIAGNOSTICS
    --------------
       United States                          $313,603         $307,721           1.9
       International                           328,445          283,743          15.8
    -------------                              -------          -------
    TOTAL                                     $642,048         $591,464           8.6
    -----                                     --------         --------           ---

    BD BIOSCIENCES
    --------------
       United States                          $124,619         $124,009           0.5
       International                           229,537          199,117          15.3
    -------------                              -------          -------
    TOTAL                                     $354,156         $323,126           9.6
    -----                                     --------         --------           ---

    TOTAL REVENUES
    --------------
       United States                          $842,523         $831,961           1.3
       International                         1,208,272        1,041,234          16.0
    -------------                            ---------        ---------
    TOTAL                                   $2,050,795       $1,873,195           9.5
    -----                                   ----------       ----------           ---

                                                                               Page 3


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)

                                                 Twelve Months Ended September 30,
                                                    2011             2010      % Change
                                                    ----             ----      --------

    BD MEDICAL
    ----------
       United States                        $1,625,044       $1,596,336           1.8
       International                         2,382,260        2,200,096           8.3
    -------------                            ---------        ---------
    TOTAL                                   $4,007,304       $3,796,432           5.6
    -----                                   ----------       ----------           ---

    BD DIAGNOSTICS
    --------------
       United States                        $1,245,872       $1,214,288           2.6
       International                         1,234,605        1,104,591          11.8
    -------------                            ---------        ---------
    TOTAL                                   $2,480,477       $2,318,879           7.0
    -----                                   ----------       ----------           ---

    BD BIOSCIENCES
    --------------
       United States                          $484,853         $475,941           1.9
       International                           856,270          781,081           9.6
    -------------                              -------          -------
    TOTAL                                   $1,341,123       $1,257,022           6.7
    -----                                   ----------       ----------           ---

    TOTAL REVENUES
    --------------
       United States                        $3,355,769       $3,286,565           2.1
       International                         4,473,135        4,085,768           9.5
    -------------                            ---------        ---------
    TOTAL                                   $7,828,904       $7,372,333           6.2
    -----                                   ----------       ----------           ---

                                                                               Page 4


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30,
    (Unaudited; Amounts in thousands)

                                                       United States
                                                       -------------
                                                  2011             2010  % Change
                                                  ----             ---- --------

    BD MEDICAL
    ----------
       Medical Surgical Systems             $246,746         $256,290      (3.7)
       Diabetes Care                         104,819           98,633       6.3
       Pharmaceutical Systems                 52,736           45,308      16.4
    TOTAL                                   $404,301         $400,231       1.0
    -----                                   --------         --------       ---

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                $161,556         $162,024      (0.3)
       Diagnostic Systems                    152,047          145,697       4.4
    ------------------                       -------          -------
    TOTAL                                   $313,603         $307,721       1.9
    -----                                   --------         --------       ---

    BD BIOSCIENCES
    --------------
       Cell Analysis                         $89,899          $86,765       3.6
       Discovery Labware                      34,720           37,244      (6.8)
    -----------------                         ------           ------
    TOTAL                                   $124,619         $124,009       0.5
    -----                                   --------         --------       ---

    TOTAL UNITED STATES                     $842,523         $831,961       1.3
    -------------------                     --------         --------       ---

                                                                         Page 5


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)

                                                                          International
                                                                          -------------
                                                                                          % Change
                                                                                          --------
                                                         2011         2010       Reported   FXN      FX Impact
                                                       ----         ----      --------    ---      ---------

    BD MEDICAL
    ----------
       Medical Surgical Systems                    $288,653     $245,724           17.5      7.8         9.7
       Diabetes Care                                119,832      100,468           19.3      7.6        11.7
       Pharmaceutical Systems                       241,805      212,182           14.0      2.5        11.5
                                                                                                        ----
    TOTAL                                          $650,290     $558,374           16.5      5.8        10.7
    -----                                          --------     --------           ----      ---        ----

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                       $167,044     $144,421           15.7      5.7        10.0
       Diagnostic Systems                           161,401      139,322           15.8      6.2         9.6
    ------------------
    TOTAL                                          $328,445     $283,743           15.8      5.9         9.9
    -----                                          --------     --------           ----      ---         ---

    BD BIOSCIENCES
    --------------
       Cell Analysis                               $183,259     $160,230           14.4      6.8         7.6
       Discovery Labware                             46,278       38,887           19.0      9.5         9.5
    -----------------
    TOTAL                                          $229,537     $199,117           15.3      7.3         8.0
    -----                                          --------     --------           ----      ---         ---

    TOTAL INTERNATIONAL                          $1,208,272   $1,041,234           16.0      6.1         9.9
    -------------------                          ----------   ----------           ----      ---         ---

                                                                                                      Page 6


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)

                                                                           Total
                                                                           -----
                                                                                       % Change
                                                                                       --------
                                                         2011         2010    Reported   FXN      FX Impact
                                                       ----         ----   --------    ---      ---------

    BD MEDICAL
    ----------
       Medical
        Surgical
        Systems                                    $535,399     $502,014         6.7      1.9         4.8
       Diabetes Care                                224,651      199,101        12.8      7.0         5.8
       Pharmaceutical
        Systems                                     294,541      257,490        14.4      4.9         9.5
    TOTAL                                        $1,054,591     $958,605        10.0      3.8         6.2
    -----                                        ----------     --------        ----      ---         ---

    BD DIAGNOSTICS
    --------------
       Preanalytical
        Systems                                    $328,600     $306,445         7.2      2.5         4.7
       Diagnostic
        Systems                                     313,448      285,019        10.0      5.2         4.8
       ----------
    TOTAL                                          $642,048     $591,464         8.6      3.8         4.8
    -----                                          --------     --------         ---      ---         ---

    BD BIOSCIENCES
    --------------
       Cell Analysis                               $273,158     $246,995        10.6      5.7         4.9
       Discovery Labware                             80,998       76,131         6.4      1.6         4.8
    -----------------
    TOTAL                                          $354,156     $323,126         9.6      4.7         4.9
    -----                                          --------     --------         ---      ---         ---

    TOTAL REVENUES                               $2,050,795   $1,873,195         9.5      4.0         5.5
    --------------                               ----------   ----------         ---      ---         ---

                                                                                                   Page 7


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30,
    (Unaudited; Amounts in thousands)

                                                         United States
                                                         -------------
                                                    2011             2010  % Change
                                                    ----             ---- --------

    BD MEDICAL
    ----------
       Medical Surgical Systems               $980,326       $1,007,322      (2.7)
       Diabetes Care                           400,809          383,783       4.4
       Pharmaceutical Systems                  243,909          205,231      18.8
    TOTAL                                   $1,625,044       $1,596,336       1.8
    -----                                   ----------       ----------       ---

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                  $643,180         $627,421       2.5
       Diagnostic Systems                      602,692          586,867       2.7
    ------------------                         -------          -------
    TOTAL                                   $1,245,872       $1,214,288       2.6
    -----                                   ----------       ----------       ---

    BD BIOSCIENCES
    --------------
       Cell Analysis                          $342,322         $326,916       4.7
       Discovery Labware                       142,531          149,025      (4.4)
    -----------------                          -------          -------
    TOTAL                                     $484,853         $475,941       1.9
    -----                                     --------         --------       ---

    TOTAL UNITED STATES                     $3,355,769       $3,286,565       2.1
    -------------------                     ----------       ----------       ---

                                                                           Page 8


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)

                                                                           International
                                                                           -------------
                                                                                           % Change
                                                                                           --------
                                                          2011         2010       Reported   FXN      FX Impact
                                                        ----         ----      --------    ---      ---------

    BD MEDICAL
    ----------
       Medical Surgical Systems                   $1,101,407   $1,002,687            9.8      3.5         6.3
       Diabetes Care                                 465,668      401,976           15.8      9.1         6.7
       Pharmaceutical Systems                        815,185      795,433            2.5     (1.9)        4.4
    TOTAL                                         $2,382,260   $2,200,096            8.3      2.6         5.7
    -----                                         ----------   ----------            ---      ---         ---

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                        $634,613     $570,386           11.3      4.9         6.4
       Diagnostic Systems                            599,992      534,205           12.3      5.8         6.5
    ------------------
    TOTAL                                         $1,234,605   $1,104,591           11.8      5.4         6.4
    -----                                         ----------   ----------           ----      ---         ---

    BD BIOSCIENCES
    --------------
       Cell Analysis                                $682,123     $624,322            9.3      4.0         5.3
       Discovery Labware                             174,147      156,759           11.1      4.1         7.0
    -----------------
    TOTAL                                           $856,270     $781,081            9.6      4.0         5.6
    -----                                           --------     --------            ---      ---         ---

    TOTAL INTERNATIONAL                           $4,473,135   $4,085,768            9.5      3.6         5.9
    -------------------                           ----------   ----------            ---      ---         ---

                                                                                                       Page 9


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)

                                                                            Total
                                                                            -----
                                                                                        % Change
                                                                                        --------
                                                          2011         2010    Reported   FXN      FX Impact
                                                        ----         ----   --------    ---      ---------

    BD MEDICAL
    ----------
       Medical Surgical Systems                   $2,081,733   $2,010,009         3.6      0.4         3.2
       Diabetes Care                                 866,477      785,759        10.3      6.8         3.5
       Pharmaceutical Systems                      1,059,094    1,000,664         5.8      2.4         3.4
    TOTAL                                         $4,007,304   $3,796,432         5.6      2.3         3.3
    -----                                         ----------   ----------         ---      ---         ---

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                      $1,277,793   $1,197,807         6.7      3.7         3.0
       Diagnostic Systems                          1,202,684    1,121,072         7.3      4.2         3.1
    ------------------
    TOTAL                                         $2,480,477   $2,318,879         7.0      3.9         3.1
    -----                                         ----------   ----------         ---      ---         ---

    BD BIOSCIENCES
    --------------
       Cell Analysis                              $1,024,445     $951,238         7.7      4.3         3.4
       Discovery Labware                             316,678      305,784         3.6        -         3.6
    -----------------
    TOTAL                                         $1,341,123   $1,257,022         6.7      3.2         3.5
    -----                                         ----------   ----------         ---      ---         ---

    TOTAL REVENUES                                $7,828,904   $7,372,333         6.2      2.9         3.3
    --------------                                ----------   ----------         ---      ---         ---

                                                                                                   Page 10


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    SAFETY REVENUES
    (Unaudited; Amounts in thousands)

                                                        Three Months Ended September 30,
                                                        --------------------------------
                                                                                         % Change
                                                                                         --------
                                              2011            2010       Reported          FXN      FX Impact
                                              ----            ----      --------           ---      ---------

    TOTAL SAFETY REVENUES
    ---------------------
       United States                    $288,541        $282,968            2.0             2.0           -
       International                     209,209         160,396           30.4            18.5        11.9
    -------------                        -------         -------           ----                        ----
    TOTAL                               $497,750        $443,364           12.3             7.9         4.4
    -----                               --------        --------           ----             ---         ---

    BY SEGMENT
    ----------
       BD Medical                       $243,521        $208,822           16.6            12.4         4.2
       BD Diagnostics                    254,229         234,542            8.4             4.0         4.4
    --------------                       -------         -------            ---                         ---
    TOTAL                               $497,750        $443,364           12.3             7.9         4.4
    -----                               --------        --------           ----             ---         ---

                                                   Twelve Months Ended September 30,
                                                   ---------------------------------
                                                                                     % Change
                                                                                     --------
                                            2011            2010       Reported          FXN      FX Impact
                                            ----            ----      --------           ---      ---------

    TOTAL SAFETY REVENUES
    ---------------------
       United States                  $1,116,543      $1,108,431            0.7             0.7           -
       International                     754,739         621,913           21.4            13.6         7.8
    -------------                        -------         -------           ----                         ---
    TOTAL                             $1,871,282      $1,730,344            8.1             5.4         2.7
    -----                             ----------      ----------            ---             ---         ---

    BY SEGMENT
    ----------
       BD Medical                       $885,156        $819,084            8.1             5.4         2.7
       BD Diagnostics                    986,126         911,260            8.2             5.3         2.9
    --------------                       -------         -------            ---                         ---
    TOTAL                             $1,871,282      $1,730,344            8.1             5.4         2.7
    -----                             ----------      ----------            ---             ---         ---

                                                                                                    Page 11


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    FY2011 Quarter-to-Date Reconciliation
    (Unaudited; Amounts in millions, except per share data)

                                                                             Three Months Ended September 30,
                                                                             --------------------------------
                                                             Reported       Impairment       Adjusted       Reported Adjusted
                                                              FY 2011       Charge (1)       FY 2011         FY 2010 % Growth
                                                              -------       ----------       -------         ------- --------

    Diluted Earnings per Share
    from Continuing Operations                                 $1.36            $0.03         $1.39           $1.24     12.1%

    (1) Represents a non-cash impairment charge resulting from the
        discontinuance of a research program within the Diagnostic Systems unit.

    All figures rounded. Totals may not add due to rounding.

                                                                                                                     Page 12


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    FY2011 Year-to-Date Reconciliation
    (Unaudited; Amounts in millions, except per share data)

                                                                                       Twelve Months Ended September 30,
                                                                                       ---------------------------------
                                                             Reported       Impairment   Adjusted       Reported                Adjusted Adjusted
                                                              FY 2011       Charge (1)   FY 2011         FY 2010        Tax (2) FY 2010  % Growth
                                                              -------       ----------   -------         -------        ------- -------  --------

    Diluted Earnings per Share
    from Continuing Operations                                 $5.59            $0.03     $5.62           $4.90          $0.04   $4.94      13.8%

    (1) Represents a non-cash impairment charge resulting from the
        discontinuance of a research program within the Diagnostic Systems unit.
    (2) Represents a non-cash charge related to healthcare reform
        impacting Medicare Part D reimbursements.

    All figures rounded. Totals may not add due to rounding.
                                                                                                                                         Page 13


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    Quarter-to-Date Fiscal 2011 Reconciliation - FX Impact
    (Unaudited; Amounts in millions, except per share data)

                                                                                                 Three Months Ended September 30,
                                                                                                 --------------------------------
                                                                                                                           FY10                  Adjusted
                                                                 Adjusted       Reported    Adjusted         Foreign           Hedge      Total         FXN         FXN
                                                                                         Growth         Currency
                                                              FY 2011       FY 2010            $       Translation         Gain        FX         Change      Growth
                                                            -------       -------          ---       -----------         ----        ---        ------      ------

    REVENUES                                                  $2,051         $1,873       $178              $115           $(11)      $103          $74         4.0%

    Diluted Earnings per Share
    from Continuing Operations                                 $1.39          $1.24      $0.15             $0.08         $(0.03)     $0.05        $0.10         8.1%

    All figures rounded. Totals may not add due to rounding.
    FXN = Foreign Currency Neutral

                                                                                                                                                            Page 14


    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    Year-to-Date Fiscal 2011 Reconciliation - FX Impact
    (Unaudited; Amounts in millions, except per share data)

                                                                                                 Twelve Months Ended September 30,
                                                                                                 ---------------------------------
                                                                                                                           FY10                  Adjusted
                                                                 Adjusted       Adjusted    Adjusted         Foreign           Hedge      Total         FXN         FXN
                                                                                         Growth         Currency
                                                              FY 2011       FY 2010            $       Translation         Loss        FX         Change      Growth
                                                            -------       -------          ---       -----------         ----        ---        ------      ------

    REVENUES                                                  $7,829         $7,372       $457              $208            $31       $240         $217          2.9%

    Diluted Earnings per Share
    from Continuing Operations                                 $5.62          $4.94      $0.68             $0.20          $0.08      $0.28        $0.40          8.1%

    All figures rounded. Totals may not add due to rounding.
    FXN = Foreign Currency Neutral

                                                                                                                                                             Page 15

SOURCE BD (Becton, Dickinson and Company)


Source: PR Newswire